Technical Analysis for LABP - Landos Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Historical LABP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 5.63% | |
| New 52 Week Closing High | Bullish | -2.97% | |
| NR7 | Range Contraction | -2.97% | |
| NR7-2 | Range Contraction | -2.97% | |
| NR7 | Range Contraction | -1.40% | |
| New 52 Week Closing High | Bullish | -1.95% | |
| Hot IPO Pullback | Bullish Swing Setup | 2.03% | |
| NR7 | Range Contraction | 2.03% | |
| NR7-2 | Range Contraction | 2.03% | |
| Hot IPO Pullback | Bullish Swing Setup | 8.23% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above 10 DMA | about 1 hour ago | |
| Up 5% | about 1 hour ago | |
| Gap Down Closed | about 2 hours ago | |
| 60 Minute Opening Range Breakout | about 2 hours ago | |
| Hot IPO Pullback Entry | about 2 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Diseases Rheumatoid Arthritis Gastroenterology Inflammatory Bowel Disease Colitis Ulcerative Colitis Diarrhea Abdominal Pain Diabetic Nephropathy Crohn's Disease Inflammatory Bowel Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Diseases Rheumatoid Arthritis Gastroenterology Inflammatory Bowel Disease Colitis Ulcerative Colitis Diarrhea Abdominal Pain Diabetic Nephropathy Crohn's Disease Inflammatory Bowel Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.35 |
| 52 Week Low | 10.77 |
| Average Volume | 572,711 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 13.86 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.06 |
| MACD Signal Line | 0.02 |
| MACD Histogram | 0.0399 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.74 | ||||
| Resistance 3 (R3) | 14.72 | 14.24 | 14.50 | ||
| Resistance 2 (R2) | 14.24 | 13.88 | 14.24 | 14.42 | |
| Resistance 1 (R1) | 13.78 | 13.65 | 13.54 | 13.79 | 14.34 |
| Pivot Point | 13.29 | 13.29 | 13.17 | 13.30 | 13.29 |
| Support 1 (S1) | 12.83 | 12.93 | 12.59 | 12.85 | 12.30 |
| Support 2 (S2) | 12.35 | 12.71 | 12.35 | 12.22 | |
| Support 3 (S3) | 11.89 | 12.35 | 12.14 | ||
| Support 4 (S4) | 11.90 |
